TARO — Taro Pharmaceutical Industries Income Statement
0.000.00%
Last trade - 00:00HealthcareBalancedMid Cap
- $1.62bn
- $735.77m
- $629.18m
Annual income statement for Taro Pharmaceutical Industries, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 6-K |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 645 | 549 | 561 | 573 | 629 |
| Cost of Revenue | |||||
| Gross Profit | 400 | 297 | 293 | 268 | 305 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 398 | 963 | 498 | 555 | 608 |
| Operating Profit | 247 | -414 | 63.5 | 17.7 | 21.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 298 | -391 | 77.9 | 38.2 | 82.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 245 | -401 | 58.3 | 25.4 | 53.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 244 | -387 | 58.3 | 25.4 | 53.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 244 | -387 | 58.3 | 25.4 | 53.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 6.35 | -0.611 | 2.77 | 0.677 | 1.43 |